China SXT Pharmaceuticals (SXTC) Receivables - Other (2018 - 2025)

China SXT Pharmaceuticals' Receivables - Other history runs 8 years deep, the most recent figure standing at $1.4 million for Q3 2025.

• In Q3 2025, Receivables - Other rose 1235.88% year-over-year to $1.4 million; the TTM figure through Sep 2025 stood at $1.4 million (up 1235.88% YoY), while the FY2025 annual figure was $417563.0, up 399.27% from the prior year.
• Receivables - Other was $1.4 million for Q3 2025 at China SXT Pharmaceuticals, up from $417563.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $3.0 million in Q3 2021 to a low of -$120122.0 in Q3 2024.
• Historically, Receivables - Other has averaged $939863.8 across 5 years, with a median of $417563.0 in 2025.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other slumped 63.74% in 2024, then surged 1235.88% in 2025.
• A 5-year view of Receivables - Other shows it stood at $3.0 million in 2021, then slipped by 7.72% to $2.7 million in 2022, then tumbled by 91.61% to $230642.0 in 2023, then slumped by 152.08% to -$120122.0 in 2024, then soared by 1235.88% to $1.4 million in 2025.
• The last three Receivables - Other figures came in at $1.4 million (Q3 2025), $417563.0 (Q1 2025), and -$120122.0 (Q3 2024), per Business Quant data.